Serological tumour markers: An introduction: J. E. Roulston and R. C. F. Leonard. Churchill Livingstone, Edinburgh, 1993. No. of pages: 192. £40.00

Autor: Philip P. B. James

Publikováno v: Hematological Oncology. 11:207-207

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ba25479ec2d9683b9787dd0b1603cc0
https://doi.org/10.1002/hon.2900110406

Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer

Autor: Charles E. Massie, G.R. Kerr, R. C. F. Leonard, David Cameron

Publikováno v: British Journal of Cancer
Cameron, D A, Massie, C, Kerr, G & Leonard, R C F 2003, ' Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer ', British Journal of Cancer, vol. 89, no. 10, pp. 1837-42 . https://doi.org/10.1038/sj.bjc.6601366

Despite the extensive literature clearly demonstrating the survival benefit for adjuvant chemotherapy in women with operable breast cancer, there are few data confirming this in routine practice. Some studies have suggested that not all women gain to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f43cb15dddc7dafcd96b1d0dcfa63103
https://doi.org/10.1038/sj.bjc.6601366

Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer

Autor: R. C. F. Leonard

Publikováno v: British Journal of Cancer

Although drugs such as the taxoids and vinorelbine have increased the options available for anthracycline-resistant metastatic breast cancer, new therapeutic options are needed, particularly for taxoid-refractory tumours. Increasing emphasis is being

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23cc64279273810f582f2df5a2aec1ec
https://doi.org/10.1054/bjoc.2001.1819

High Dose Ifosfamide in Combination with Etoposide and Epirubicin Followed by Autologous Stem Cell Transplantation in the Treatment of Relapsecd/Refractory Hodgkin's Disease: a Report on Toxicity and Efficacy On behalf of the Scotland and Newcastle Lymphoma Group

Autor: Brian Angus, K. Windebank, D Goff, McQuaker Ig, Nigel H. Russell, M. J. Galloway, P. J. Carey, R. D. Finney, S. J. Proctor, Penny Taylor, Anne Lennard, Graham Jackson, R. C. F. Leonard, A P Haynes

Publikováno v: Leukemia & Lymphoma. 37:561-570

Patients with Hodgkin's disease (HD) refractory to first line chemotherapy and those who have rapid or multiple relapses have a very poor prognosis. With the increasing use of hybrid chemotherapy these patients will have been exposed to many of the d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c1859a082846605f874f99a8f857195
https://doi.org/10.3109/10428190009058508

MIB-1 in relation to tumour response and survival in patients with breast cancer treated with primary systemic therapy

Autor: M A McIntyre, R. C. F. Leonard, A.P.M. Forrest, E.P. Miller, Udi Chetty, E. D. C. Anderson, P. A. Levack, David Cameron, William R. Miller

Publikováno v: The Breast. 8:77-83

The expression of MIB-1, a marker of proliferation, has been measured in tumours from 61 patients with large (>4 cm) operable breast cancers (T2,3 N0,1M,) treated with primary systemic therapy; either with hormone therapy (27 patients), chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::597b3b0359de33e64164e433fe959987
https://doi.org/10.1016/s0960-9776(99)90004-8